Mechanism of action and clinical research progress of trilaciclib in bone marrow protection
QIAN Min-jia
JIN Ge
FU Ling-ling
XU Min
CHEN He-jian
ZHOU Jian-ying
CHEN Pei-feng
Abstract：Chemotherapy-induced myelosupression(CIM)is the most common toxicity of chemotherapy drugs.Usually,more than 80%of chemotherapy drugs lead to myelosuppression,and CIM is usually characterized by neutropenia,thrombocytopenia and erythrocytopenia.Dose reduction and delayed administration of chemotherapy drugs by CIM seriously reduce the life quality of patients and the overall anti-tumor effect of chemotherapy.As the first drug approved for bone marrow protection,trilaciclib is a highly effective,selective and reversible cyclin-dependent kinase(CDK)4/6 inhibitor,which can temporarily block cell cycle of hematopoietic stem/progenitor cells and immune cells in G1 phase,so as to reduce the damage caused by chemotherapy and protect bone marrow protection.In April 2021,trilaciclib was approved by FDA as a myelo preservation in the United States.In July 2022,trilaciclib was approved by the National Medical Products Administration for marketing in China,and the first indication of trilaciclib in China was for patients with extensive stage small-cell lung cancer.In this review,the mechanisms of action,pharmacokinetics,drug interaction mechanism,clinical evaluation,safety and other related research progress of trilaciclib are systematically reviewed,aiming to provide further reference and basis for clinical practice.
Keywords：chemotherapy-induced myelosupressionchemotherapy drugstrilaciclibimmune regulationsurvival benefit
Publication Date：2023-12-15
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：8( 2339-2346 )